APA (7th ed.) Citation

Novella-Navarro, M., Ruiz-Esquide, V., López-Juanes, N., Chacur, C. A., Monjo-Henry, I., Nuño, L., . . . Balsa, A. (2024). Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria. Clinical Rheumatology: Journal of the International League of Associations for Rheumatology, 43(9), 2817-2823. https://doi.org/10.1007/s10067-024-07070-8

Chicago Style (17th ed.) Citation

Novella-Navarro, Marta, et al. "Subsequent Biologic and Targeted Synthetic Disease Modifying Anti Rheumatic Drugs After Fulfilling Difficult-to-treat Rheumatoid Arthritis Criteria." Clinical Rheumatology: Journal of the International League of Associations for Rheumatology 43, no. 9 (2024): 2817-2823. https://doi.org/10.1007/s10067-024-07070-8.

MLA (9th ed.) Citation

Novella-Navarro, Marta, et al. "Subsequent Biologic and Targeted Synthetic Disease Modifying Anti Rheumatic Drugs After Fulfilling Difficult-to-treat Rheumatoid Arthritis Criteria." Clinical Rheumatology: Journal of the International League of Associations for Rheumatology, vol. 43, no. 9, 2024, pp. 2817-2823, https://doi.org/10.1007/s10067-024-07070-8.